Acadia Pharmaceuticals Inc.

ACAD
Marechal v. Acadia Pharmaceuticals Inc. et al.

After the markets closed on March 8, 2021, Acadia announced that on March 3, 2021, the FDA informed Acadia, as part of the FDA’s ongoing review of Acadia’s supplemental New Drug Application, that the FDA had “identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.” On this news, shares have fallen precipitously in after-market trading.

Lead Plaintiff deadline
June 18, 2021
class period
June 15, 2020
to
April 4, 2021
Case Documents
No documents available. Contact us if you need a case document.